Articles tagged with Ovarian Cancer
Researchers at Ohio State University have discovered a promising therapy combining an oncolytic virus with doxorubicin to treat advanced or recurrent ovarian cancer. The treatment showed significant antitumor activity in animal models, increasing survival and inducing programmed cell death in cancer cells.
Researchers at Lund University discovered that lactose intolerant people are at a reduced risk of developing lung, breast, and ovarian cancers. The study, which analyzed nationwide data from Sweden, suggests that diet plays a crucial role in protecting against these cancers.
Tea and citrus fruits/juices associated with reduced risk of developing ovarian cancer. Flavonols/flavanones found in foods high in these compounds significantly decrease ovarian cancer risk.
A recent study found that a higher overall diet quality was associated with a lower risk of mortality among ovarian cancer survivors. The composite effect of healthy dietary choices on survival suggests that individual components may not be as crucial as previously thought.
A study by Myriad Genetics presented at the 2014 European Society for Medical Oncology (ESMO) annual meeting shows that its Tumor BRACAnalysis CDx test identifies cancer-causing BRCA1/2 mutations in 44% more patients than germline blood testing. This could expand treatment options for ovarian cancer patients with these genetic mutations.
A study of over 93,000 women found that increases in skirt size are strongly associated with a higher risk of postmenopausal breast cancer. Women who gained one size every 10 years were 33% more likely to develop the disease, while those who gained two sizes faced an 77% greater risk.
A recent study published in PNAS reveals the link between gelsolin protein and ovarian cancer resistance, providing a promising avenue for developing new therapies. By cutting down gelsolin levels, researchers found that chemo-resistant cells become susceptible to chemotherapy.
Research finds HE4 hormone plays key role in modulating ovarian cancer response to hormones and therapies. The study identified a mechanism by which hormonal therapies like Tamoxifen and Fulvestrant restore sensitivity to chemotherapy in HE4-overexpressing tumors.
Ovarian cancer cells use mesothelial cells to spread through the body via fibronectin secretion. The study suggests that mesothelium is an active participant in the spread of ovarian cancer.
A phase Ib clinical trial found that olaparib tablets were safe and effective in heavily pretreated ovarian cancer patients, particularly those with BRCA mutations. The treatment regimen provided a response rate of 66 percent and no grade 4 toxicities, making it a promising option for improving cure rates and quality of life.
A team led by Lin Zhang identified a non-protein-coding RNA, FAL1, whose expression is linked to ovarian cancer. The study found that blocking the activity of FAL1 reduces cancer cells' growth and may serve as a biomarker for BRCA-related cancer prognosis.
Researchers at A*STAR's Institute of Medical Biology have identified a biomarker, Lgr5, to detect ovarian cancer earlier. Bioinformatics analysis has also revealed genes whose mutation status can be used for prognosis and development of personalized treatment.
Researchers at MD Anderson Cancer Center have discovered that circulating tumor cells (CTCs) rely on the HER3 receptor protein to metastasize to the omentum, a fatty tissue covering abdominal organs. High expression of HER3 is associated with shorter survival in ovarian cancer patients.
A 30-year follow-up study found no link between fertility drugs and breast, ovarian, and uterine cancers, except for extended use of clomiphene citrate. The study of 12,193 women treated for infertility showed a higher risk of invasive breast cancer with clomiphene use in 12 or more treatment cycles.
Researchers at St. Joseph's Hospital and Medical Center discovered a new treatment for ovarian cancer that improves response rates and prolongs time until cancer recurrence. Trebananib, a peptide-Fc fusion protein, targets angiogenesis by inhibiting angiopoietin 1 and 2 binding to the Tie2 receptor.
Researchers have discovered a protein called focal adhesion kinase (FAK) that plays a crucial role in ovarian cancer cell growth. A network of signals generated by osteopontin and FAK controls spheroid growth, making it a potential target for new therapies.
A study published in JNCI: Journal of the National Cancer Institute found that a shorter time to first cigarette (TTFC) is associated with an increased risk of lung cancer in both heavy and light smokers. The researchers analyzed data from over 3,200 current and former smokers, revealing that TTFC was statistically significantly higher...
Researchers at the University of Adelaide have identified a genetic pathway that suppresses the spread of ovarian cancer. By studying the genetics of platypus and humans, they found that piRNA genes play a crucial role in preventing the growth of cancer cells.
The Myriad myRisk test detects significantly more deleterious mutations than single cancer tests and helps solve the overlap dilemma among hereditary cancer syndromes. The test evaluates 25 clinically significant genes associated with eight major hereditary cancers.
Researchers used gene expression arrays to analyze biopsies from ICON7 patients and found that patients with proliferative and mesenchymal subtypes responded best to bevacizumab. This subtype analysis may help identify patients who will benefit from the treatment, potentially reducing unnecessary toxicity.
A phase I and II clinical trial demonstrated a near doubling of progression-free survival benefit for the combination therapy compared to olaparib alone. The study results showed significant improvement with the use of the combination drug therapy for recurrent ovarian cancer, suggesting a new treatment option for patients.
A clinical trial has shown that a combination of drugs, including olaparib and cediranib, can significantly improve progression-free survival for patients with recurrent ovarian cancer. The study found that the combination therapy doubled the benefit of using olaparib alone.
Researchers at Mount Sinai present promising findings on innovative treatments for recurrent ovarian cancer, molecular profiling of bile duct and gallbladder cancers, and adjuvant therapy for melanoma. The studies demonstrate encouraging results for patients with these rare and often fatal diseases.
A new study of women with BRCA mutations who underwent risk-reducing salpingo-oophorectomy found high rates of sexual dysfunction, menopausal symptoms, and poor sleep. Hormone replacement therapy provided relief for some patients, highlighting the need for better strategies to manage long-term effects.
An analysis by Fox Chase Cancer Center has revealed a dramatic increase in the use of chemotherapy before surgery to remove ovarian cancer, with 26.72% of patients receiving it in 2011 compared to 8.94% in 1998.
A meta-analysis of 44 studies found that breastfeeding, tubal ligation, and oral contraceptives are associated with reduced rates of ovarian cancer in BRCA1 mutation carriers. Smoking may raise the risk of breast cancer for patients with a BRCA2 mutation.
A recent study published in the Journal of Community Genetics found that only one in twenty-two high-risk women received BRCA genetic counseling. Despite having a diverse population, no significant differences were associated with factors like age, race, or family size. The researchers urge providers and patients to be more aware of th...
A new study found that ovarian cancer cells become more aggressive and proliferate faster when adhering to soft tissues compared to stiffer environments. The research team used novel techniques to measure cell forces, revealing a three-fold increase in traction forces on soft surfaces for metastatic cells.
Researchers found a key indicator of ovarian cancer aggressiveness in the glutamine ratio between external and internal sources. A high ratio is associated with tumor aggression and poor survival rates.
Researchers at Georgia State University identify two enzymes that suppress proteins important for cell survival and chemoresistance in ovarian cancer. Their findings suggest inhibiting these enzymes could be a novel therapeutic approach to overcoming resistance.
A new study elucidates how BRCA gene loss accelerates chromosome rearrangements, impairing homologous recombination repair. This discovery could help clinicians guide patient treatment for BRCA mutations of uncertain significance.
Scientists have identified a potential new strategy to treat ovarian cancer by targeting multiple growth factors. By blocking several avenues that tumour cells use to escape eradication, researchers hope to develop new anticancer drugs that target ovarian tumour growth.
Researchers inhibit heat shock protein 90, shutting off proteases that help ovarian cancer cells escape and spread. In mouse studies, ganetespib treatment reduced metastases, indicating potential therapeutic target for ovarian cancer.
The Bezos family's $20 million donation will support the development of novel cancer immunotherapies for various solid tumor cancers. The gift promises to save lives by expanding the use of immunotherapy to treat a range of deadly cancers.
Researchers at Fox Chase Cancer Center have identified FAK as a potential target for epithelial ovarian cancer treatment. By inhibiting the activity of FAK, they found that STAT3 activation was reduced, suggesting that targeting this enzyme could also inhibit the action of STAT3 in epithelial ovarian cancer cells.
Researchers from Fox Chase Cancer Center found that NEDD9 protein activates oncogenic signaling pathways in cancer cells, encouraging metastases. The study suggests the protein plays an important role in initial development and dissemination of ovarian cancer.
Researchers uncover complement pathway as primary immune mechanism driving endometriosis and ovarian cancer development. The discovery may lead to targeted preventive measures, such as immune therapy, for women with endometriosis at increased cancer risk.
Researchers discovered two new genes, NEIL2 and OGG1, that modulate the risk of breast and ovarian cancer in women with high-risk mutations. The genes affect an alternative DNA repair pathway and may have implications for treatments like PARP inhibitors.
A new study found that ovarian cancer patients' disease-free survival rates significantly improved over time, particularly among those with poorer initial prognoses. The research suggests that considering the time elapsed since remission may provide a more accurate prognosis and inform better follow-up care decisions.
Researchers at the University of Texas MD Anderson Cancer Center found that blocking prolactin signaling can induce autophagy in cancer cells, leading to their death. In preclinical research, treatment with a prolactin-mimicking peptide reduced tumor weight by 50% and led to increased expression of autophagy genes.
A groundbreaking study led by TGen has identified a genetic mutation in the SMARCA4 gene as the primary driver of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), a rare and aggressive form of ovarian cancer. This discovery holds promise for developing targeted therapies and improving diagnosis.
Scientists have identified a set of proteins called TAFs that may play a role in the development of ovarian cancer. Studies found that these proteins are overexpressed or underexpressed in 73% of tumors, suggesting they could be potential targets for new treatments.
A new glycoprofiling test has been developed to halve the number of false-positives in ovarian cancer diagnoses, sparing women from unnecessary worry and further testing. The test targets a specific sugar molecule on the CA125 protein, which is only present in women with ovarian cancer.
Researchers at Tel Aviv University propose a new nanoscale drug-delivery system to tackle aggressive ovarian cancer using a cluster of nanoparticles called gagomers. The system accumulates in tumors, producing dramatic therapeutic benefits and reducing toxic accumulation in healthy organs.
A large international study found that women with BRCA1 mutations who underwent preventive ovarian surgery before age 35 had a 77% reduction in total mortality risk. In contrast, women with BRCA2 mutations may delay this procedure until their 40s.
Researchers have developed a biologic drug that prevents the production of HE4 protein, allowing ovarian cancer cells to grow aggressively and resist chemotherapy. The novel biologic has shown promising results in cell and animal models, increasing the potential for improved treatment and survival rates for women with ovarian cancer.
A University of Colorado study used a COXEN model to match tumors with optimal drugs, significantly extending patient survival. The model analyzed genetic data from thousands of tumor samples to identify response patterns.
Two proteins, phospholipase Cγ1 and growth factor receptor bound protein 2 (Grb2), compete for binding to FGFR2 with distinct effects on cancer cell behavior. High levels of Plcγ1 lead to increased metastasis, while high Grb2 levels inhibit this process.
The University of South Florida and FORCE have received a PCORI award to expand a health data network for hereditary breast and ovarian cancer research. The ABOUT Network will collect comprehensive clinical data, engage patients, and advance patient-centered studies.
A new study estimates that one in five women with ovarian cancer has an inherited genetic mutation that increases their risk of developing the disease. The research identified 222 inherited genetic variants associated with ovarian cancer, including major changes in genes critical for DNA repair and cell division.
Researchers at Case Comprehensive Cancer Center have identified a microRNA biomarker, miR-181a, that predicts treatment response in ovarian cancer. Elevated levels of miR-181a are associated with chemotherapy resistance and disease progression.
A study by Manchester scientists found that women who undergo risk-reducing surgery have increased survival rates compared to those who don't. The research suggests that removing ovaries and fallopian tubes can reduce the risk of both ovarian and breast cancer by half.
Researchers at Cedars-Sinai have discovered a 10-gene biomarker panel that can identify the aggressiveness of ovarian cancer, predict survival outcomes, and inform novel therapeutic strategies. The study suggests that this biomarker panel may have predictive value and biological relevance for treating patients with ovarian cancer.
Researchers at Rutgers University have developed a targeted drug delivery system that successfully treats advanced-stage ovarian cancer in mice. The treatment involves using small inhibiting RNA molecules to decrease excess CD44 protein in cancer cells while treating with anti-cancer drug paclitaxel.
A microchip-based device developed by MGH researchers may simplify the monitoring of patients' response to treatment for ovarian cancer. The team isolated and identified tumor cells from ascites, an accumulation of fluid in the abdomen that often occurs in abdominal cancers.
Scientists at Fred Hutchinson Cancer Center developed a method to count tumor-infiltrating T lymphocytes reliably and quickly, which correlates with improved survival rates. The technology has the potential to predict treatment response, cancer recurrence, and disease-free survival earlier and more effectively.
A comprehensive study reveals unprecedented genetic variation in ovarian cancer, highlighting potential new pathways for therapeutic intervention. The research suggests that sampling and sequencing of multiple disease sites may be required for effective targeted treatments.
The EORTC study found that baseline recorded health-related quality of life parameters provided additional prognostic information for survival in eleven types of cancer, including brain, breast, and colorectal cancers. The specific health-related quality of life parameters found to be predictive for survival varied by cancer site.
A study by UCL researchers found that abnormal levels of female hormones are a possible explanation for why women with BRCA1/2 mutations develop breast and ovarian cancer. The research suggests that targeting these hormones could lead to new ways of preventing cancers in high-risk women.
A new study identifies cancer-specific gene signatures for breast, lung, prostate, and ovarian cancers using surprisal analysis, a thermodynamics-based approach. This method allows researchers to understand how cellular energy is expended in cancer cells and identify potential biomarkers for early detection and therapy.